Corvus Pharmaceuticals, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
Corvus Pharmaceuticals, Inc. (CRVS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2022-11-03
- Corvus Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-09-30 was $0.00.
- Corvus Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-06-30 was $0.00.
- Corvus Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2022-03-31 was $0.00.
- Corvus Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2021-12-31 was $0.00.
- Corvus Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2021 was $0.00.
- Corvus Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2020 was $0.00.
- Corvus Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2019 was $0.00.
- Corvus Pharmaceuticals, Inc. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2018 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | $0.00 derived: sum of 3 quarters · filed 2022-08-08 | $0.00 derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-05-05 | $0.00 derived: sum of 3 quarters · filed 2022-05-05 | $0.00 derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $0.00 10-K · filed 2022-03-10 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $0.00 derived: sum of 2 quarters · filed 2021-11-01 | $0.00 10-Q · filed 2021-11-01 | $0.00 derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $0.00 10-Q · filed 2021-08-02 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $0.00 derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-29 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $0.00 derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $0.00 10-K · filed 2022-03-10 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $0.00 10-Q · filed 2020-10-29 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $0.00 10-Q · filed 2020-07-30 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-03-31 | $0.00 10-Q · filed 2020-04-30 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | $0.00 derived: sum of 2 quarters · filed 2019-10-29 | $0.00 10-Q · filed 2019-10-29 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |